Shows
Gesundheitspolitik im FokusMedizinischer Fortschritt in Gefahr? Was auf dem Spiel steht — für Patientinnen, Patienten und den Standort Schweizmit Nationalrätin Patricia von Falkenstein und Nationalrat Thomas Rechsteiner.
Ist der medizinische Fortschritt in der Schweiz in Gefahr?
Die Schweiz ist Heimat von grossen Pharmaunternehmen. Jedoch schneidet sie bei der Verfügbarkeit innovativer Medikamente im europäischen Vergleich schlecht ab. Nur 50 Prozent der in der EU zugelassenen innovativen Medikamente sind in der Schweiz über die Krankenkasse erstattet. Der sogenannte Submission Gap wächst: Pharmaunternehmen priorisieren andere Märkte, reichen Zulassungsgesuche in der Schweiz immer später ein.
Gleichzeitig steht der Standort unter Druck: von aussen durch das US-Programm GENEROUS, das Schweizer Medikamentenpreise zum globalen Referen...
2026-06-2339 min
AUTM on the AirHow Novartis Approaches External Research Collaboration with Dr. Yogesh SharmaUniversity-industry partnerships often sound straightforward from the outside. A promising discovery is made, a company sees potential, and a collaboration begins. But anyone who has worked inside these agreements knows the reality is far more complex. Research goals, publication timelines, IP rights, background technology, data sources, and internal review processes all have to be understood before a partnership can move forward in a productive way.My guest today is Dr. Yogesh Sharma, Global Head of External Research Collaboration at Novartis. In this role, he works at the intersection of academic research and corporate R&D, helping shape...
2026-06-1026 min
Gesundheitspolitik im FokusPharmabranche: Der Schweizer Konjunkturstabilisator unter Druckmit Johannes von Mandach, Head of Economic Research, Wellershoff & Partners
Der Life-Science-Sektor und die Pharmaindustrie sind für die Schweiz nicht einfach eine starke Branche unter vielen. Sie sind ein zentraler Produktivitäts-, Wachstums- und zunehmend auch fiskalischer Faktor. Ihr Anteil an der Gesamtwertschöpfung liegt gemäss Studien heute bei über zehn Prozent, und die Produktivität der Branche ist mit rund einer Million Schweizer Franken Wertschöpfung pro Vollzeitstelle enorm. Die Ökonomen von Wellershoff & Partners, haben den Sektor genauer unter die Lupe genommen. Im Gespräch werfen wir einen Blick darauf, warum diese Branche für Wachstum, Produktivi...
2026-05-2638 min
DoctorPodcasts || Cykiert FilesNovartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease.Got dry mouth, dry eyes, joint pains, chronic fatigue? Get checked for often-undiagnosed Sjögren’s Disease. Watch this video podcast with rheumatologist & Sjogren's expert, Sara McCoy, M.D. discussing Novartis #ianalumab FDA Breakthrough Therapy Designation. More information is available at: https://www.novartis.com/news/media-releases/novartis-ianalumab-receives-fda-breakthrough-therapy-designation-sjogrens-diseaseandhttps://sjogrens.org/andhttps://www.uwhealth.org/providers/sara-s-mccoy-mdandhttps://www.novartis.com/us-en/patients-and-caregiversWatch all 145 episodes of the #DoctorPodcasts || Cykiert Files video podcast interview show with physicians, scientists, healthcare specialists, entrepreneurs and other experts http://Doctorpodcasts.com/index-of-doctoof-doctoof-doctoof-doctorpodcasts-episodes. Please SUBSCRIBE & FOLLOW @DoctorPodcasts . Please LIKE, REPOST/QUOTE and SHARE the episodes. Send questions, com...
2026-05-1144 min
Gesundheitspolitik im FokusPrävention: Der unterschätzte Hebel für ein nachhaltiges Gesundheitswesenmit Ständerätin Flavia Wasserfallen und Ständerat Hannes Germann.
Prävention: Warum die Schweiz nicht vorwärtskommt
Prävention gilt als Schlüssel zu einem nachhaltigeren Gesundheitswesen – doch in der Schweiz bleibt ihr Stellenwert begrenzt. Wir werfen einen Blick darauf, warum die Prävention seit dem Scheitern des Präventionsgesetzes im Jahr 2012 politisch nicht vom Fleck kommt. In einer Tour d’horizon fragen wir: Wo stehen wir heute? Wo liegen die Blockaden? Und was braucht es, damit Prävention und Früherkennung ihr Potenzial besser entfalten können? Es geht um die Diskrepanz zwischen Krankheitsbehandlung und Krankheitsve...
2026-04-2639 min
PharmaSource PodcastNovartis on What Great CDMO Partnerships Actually Look Like“Don’t pick a CMO that just agrees with you.”Isabel Feuerstein is Head of Business Development for EU and Asia CMO at Novartis, where she shapes the company’s contract manufacturing strategy across key global markets. Mark Schiefermeier leads the manufacturing unit at DS Schaftenau, one of Novartis’ critical drug substance manufacturing facilities in Austria, overseeing technical execution and quality systems that underpin Novartis’ external manufacturing commitments.In this episode of the PharmaSource podcast, Isabel and Mark explain why technical credibility, real transparency, and a willingness to challenge clients are the foundations of a high-perform...
2026-04-1622 min
Gesundheitspolitik im FokusTarifierung: Warum der volkswirtschaftliche Nutzen von medizinischen Leistungen stärker zählen solltemit Nationalrätin und Kinderchirurgin Bettina Balmer sowie Nationalrat und Unternehmer Thomas de Courten.
Die Debatte über das Gesundheitswesen wird fast immer über Kosten geführt. Doch was ist mit dem Nutzen von medizinischen Leistungen – für Patientinnen und Patienten, für Angehörige, für den Arbeitsmarkt und für die Volkswirtschaft? Genau dieser Aspekt ist bei der Tarifierung quasi unberücksichtigt. Wir nehmen diesen blinden Fleck des volkswirtschaftlichen Nutzens für die zukünftige Gestaltung des Tarifsystems genauer unter die Lupe. Ausgangspunkt ist ein parlamentarischer Vorstoss, der den volkswirtschaftlichen Nutzen von Leistungen und Therapien in einem Pilotprojekt systematischer...
2026-03-2938 min
Gesundheitspolitik im FokusSpitallandschaft Schweiz: Wie kommt die Schweiz beim Umbau zügig voran?mit Nationalrätin Regine Sauter, Präsidentin H+ Die Spitäler der Schweiz und Nationalrat und Pflegefachmann Patrick Hässig.
Kürzlich hat die Konferenz der kantonalen Gesundheitsdirektorinnen und -direktoren (GDK) «Neuerungen für eine stärkere Zusammenarbeit in der Spitalplanung» beschlossen. Fast zeitgleich hat der Spitalverband H+ den Weg der Spitäler für eine moderne, verlässliche und finanzierbare Spitalversorgung präsentiert. Die Motion «Kosten einsparen und Qualität verbessern» will, dass die Spitalplanung vom Bund und Kantonen gemeinsam gemacht wird. Im Gespräch entwickeln wir ein Bild davon, wie der Strukturwandel am effektivsten angegangen werden kann. Wir reden darüber...
2026-02-0843 min
PETRI DISH PERSPECTIVESEpisode 33: NovartisSend us Fan MailIn this episode of Petri Dish Perspectives, we dive deep into the remarkable evolution of Novartis, one of the world’s most influential and scientifically ambitious pharmaceutical companies. From its 18th-century dye-making origins to its modern dominance in gene therapy, oncology, and complex biologics, Novartis has become a case study in strategic reinvention.We explore the company’s defining breakthroughs from Gleevec, the drug that rewrote the playbook for targeted cancer therapies, to cutting-edge innovations like CAR-T, RNA therapeutics, radioligand therapy, and AI-driven drug design. You’...
2025-12-1123 min
Gesundheitspolitik im FokusTARDOC: Das neue Tarifsystem und die Innovationmit Guido Speck, CEO des Kantonsspitals Winterthur und Verwaltungsratsmitglied von OAAT und Markus Ziegler, Gesundheitsökonom, Mitglied der Geschäftsleitung und Leiter Bereich Market bei Interpharma.
Der neue ambulante Arzttarif TARDOC und ambulante Pauschalen lösen den veralteten Tarif TARMED ab. Das führt zu einer kostenneutralen Neuverteilung der jährlich rund 13 Milliarden Franken im System. Zu reden geben vor allem die ambulanten Pauschalen. Sie tarifieren Leistungen in ressourcenintensiven Infrastrukturen der ambulanten Spezialversorgung, wie beispielsweise Operationen, aufwändige Verabreichungsformen oder Endoskopien. Wo sind die Probleme? Im Gespräch werfen wir einen Blick auf die Gewinner und Verlierer der Reform und lot...
2025-12-0939 min
Progress, Potential, and Possibilities Podcast / ShowDr. Norman Putzki, MD - SVP, Novartis - Gene Therapy And A New Era Of NeuroscienceSend us Fan MailDr. Norman Putzki, MD is Senior Vice President, Global Clinical Development Head, and U.S. Development Site Head at Novartis ( https://www.novartis.com/ ) where he oversees global teams working on next-generation gene therapies, RNA-based medicines, targeted biologics, and innovative small molecules.Dr. Putzki most recently served as Global Head of Development for Neuroscience and Gene Therapy at Novartis, where he oversaw one of the world’s most ambitious pipelines aimed at transforming the lives of patients with neurological, neuromuscular, and rare genetic diseases. A physician–scientist by training, with...
2025-12-0935 min
Gesundheitspolitik im FokusSeltene Krankheiten: Versorgungslage auf dem Prüfstandmit Nationalrätin Farah Rumy, Pflegefachfrau, NDS Pflegeberatung und Dr. Nicole Gusset, Präsidentin Schweizerische Muskelgesellschaft & SMA Schweiz, CEO SMA Europe
Das Bundesgesetz über Massnahmen zur Bekämpfung Seltener Krankheiten will die Versorgung der 650’000 Betroffenen nachhaltig absichern. Die Versorgungsstrukturen und die Arbeit der Patientenorganisationen sollen finanziell gestärkt werden. Über ein nationales Register mit Widerspruchsrecht soll das Vorkommen seltener Krankheiten systematisch erfasst und Daten für die Verbesserung von Forschung und Versorgungsqualität nutzbar gemacht werden. Im Gespräch klären wir: Wo sind die kritischen Momente in der Gesundheitsversorgung? Welche Hürden sehen Betroffene und Angehörigen? Wo drückt der Sch...
2025-11-1643 min
Employee Survival Guide®Gender Discrimination Class Action: Velez v. NovartisComment on the Show by Sending Mark a Text Message.What happens when a corporate giant like Novartis faces allegations of systemic gender discrimination? In this eye-opening episode of the Employee Survival Guide®, Mark Carey takes you deep into the shocking class action lawsuit filed by Amy Velez and her fellow female employees, revealing the pervasive gender bias that has allegedly infiltrated the very fabric of Novartis’ corporate culture. As we dissect the claims of gender discrimination, unequal promotion tracks, pay inequity, and differential treatment, you'll discover how subjective decision-making processes have allowed harmful gender stereotypes to dic...
2025-11-1219 min
Gesundheitspolitik im FokusKrebsbarometer: Vorsorge als Schlüssel für eine bessere Versorgung?mit Felix Gutzwiler, alt Ständerat, Präventivmediziner, Präsident von prio.swiss und Lukas Golder, Meinungsforscher, Co-Leiter, Präsident vom gfs.bern.
Der Krebsbarometer des Meinungsforschungsinstituts gfs.bern zeigt eine hohe Zufriedenheit der Bevölkerung mit der Krebsversorgung in der Schweiz. Besonders positiv wird die Versorgung in den Spitälern und mit Medikamenten von Betroffenen mit einer Krebserkrankung beurteilt. Doch nicht in allen Bereichen fällt das Urteil so positiv aus. Vor allem in der Krebsvorsorge verortet die Bevölkerung einen grossen Verbesserungsbedarf. Konkret geht es um Verbesserungen in der Krebsprävention und Früherkennung. Doch welche Potenziale liegen tat...
2025-10-0541 min
Gesundheitspolitik im FokusPharmastandort Schweiz unter Druck – time to take action?!mit Nationalrätin Elisabeth Schneider-Schneiter, Mitglied der aussenpolitischen Kommission und Präsidentin der Handelskammer beider Basel.
Der Pharmastandort Schweiz gilt seit Jahrzehnten als Erfolgsgeschichte – ein Motor für Wachstum, Wohlstand und Innovation. Doch die Dynamik gerät ins Stocken: langwierige innenpolitische Prozesse bremsen, die Standortattraktivität sinkt und der internationale Wettbewerb verschärft sich. Während andere Länder mit klaren Pharmastrategien vorwärtsmachen, droht die Schweiz ins Hintertreffen zu geraten. Wie können wir die Wettbewerbsfähigkeit des Standorts Schweiz im Interesse von Forschung, Volkswirtschaft und Industrie stärken? Welche Hebel müssen jetzt bewegt werden, um das Ökosystem in der...
2025-08-2942 min
In Good Company with Nicolai TangenHIGHLIGHTS: Vasant Narasimhan - CEO of NovartisWe've curated a special 10-minute version of the podcast for those in a hurry. Here you can listen to the full episode: https://podcasts.apple.com/no/podcast/novartis-ceo-medical-innovation-tech-partnerships-and/id1614211565?i=1000714438745&l=nb Can AI help us find cures for diseases we've never been able to treat? Nicolai Tangen speaks with Vasant 'Vas' Narasimhan, CEO of Novartis, about pioneering pharmaceutical innovation. They explore breakthrough cell and gene therapies, AI partnerships with leading tech companies, and how Novartis transformed from a sprawling conglomerate into a streamlined drug discovery company. Vas shares his unique p...
2025-06-2710 min
Gesundheitspolitik im FokusEFAS: Wie setzen Kassen und Kantone den Gamechanger im Schweizer Gesundheitssystem um?mit Regierungsrätin Michaela Tschuor, Gesundheits- und Sozialdirektorin des Kantons Luzern und Philomena Colatrella, CEO der CSS.
Die einheitliche Finanzierung von stationären und ambulanten Leistungen verspricht ein Gamechanger zu sein. EFAS eliminiert Fehlanreize in den bestehenden Versorgungsstrukturen und bringt die ambulante Versorgung mit Tempo voran. Die Umsetzung ist allerdings ein grösserer Akt, den die Kassen und die Kantone rasch und miteinander zu gestalten haben. Wie setzen Kassen und Kantone die grosse Reform konkret um? Wo stehen sie im Prozess und was steht über EFAS hinaus an, um das Schweizer Gesundheitssystem heute für die Zukunft fit zu mache...
2025-05-0543 min
Gesundheitspolitik im FokusZugang zu innovativen Therapien: Solidarität als Schlüsselmit Urs Bieri, Co-Leiter und Mitglied des Verwaltungsrates gfs.bern
Im Gegensatz zu klassischen Therapien setzen innovative Therapien auf Heilung und Regeneration. In der Regel sind sie hochwirksam, aber auch ressourcenintensiv. Das stellt die Akteure im Gesundheitswesen vor neue Herausforderungen. Hersteller, Leistungserbringer und Behörden arbeiten daran, Lösungen für die drängenden Fragen zu finden, die letztlich den Zugang ermöglichen. Doch wo steht die Bevölkerung in dieser Frage? Urs Bieri Co-Leiter und Mitglied des Verwaltungsrates des renommierten Meinungsforschungsinstituts gfs.bern hat Bürgerinnen und Bürger dazu befragt. Dabei wird klar: Alle sollen den gleichen Zugang z...
2025-04-0730 min
CAFC News BriefNovartis Pharmaceuticals Corporation V. Msn Pharmaceuticals, Inc., decided 4 Dec 24Novartis Pharmaceuticals Corporation appealed a district court's denial of a preliminary injunction against MSN Pharmaceuticals, Inc., preventing the launch of MSN's generic version of Entresto. The dispute centered on whether MSN's product infringed Novartis's patent for an amorphous form of a compound. The district court found Novartis did not demonstrate a likelihood of success on the merits because conflicting expert evidence existed regarding the presence of the patented amorphous form in MSN's product. The court also found that Novartis failed to prove irreparable harm. The appeals court affirmed the district court’s decision, finding no clear error in its fact...
2025-03-1912 min
Gesundheitspolitik im FokusEin Nationaler Krebsplan für die Schweiz: Der Handlungsbedarf ist dringendmit den Ständeräten Erich Ettlin und Damian Müller
Der aktuelle Podcast beleuchtet die Dringlichkeit eines Nationalen Krebsplans für die Schweiz. Die Ständeräte Erich Ettlin (Die Mitte) und Damian Müller (FDP.Die Liberalen) diskutieren mit Heike Scholten die Hintergründe für den «Nationalen Krebsplan», die Herausforderungen bei dessen Umsetzung und die erwartete Verabschiedung durch den Bundesrat im Sommer 2026. Im Gespräch wird deutlich: Die Schweiz braucht mehr Koordination in der Krebsbekämpfung, von der Früherkennung und Prävention über innovative Therapien bis zur Nachsorge. Gerade weil das Gesundheitswesen in den Kantonen angesiedelt ist...
2025-03-0541 min
Gesundheitspolitik im FokusWie solidarisch ist das Gesundheitssystem Schweiz? Die Swiss Inequality Database Health schafft Klarheit.mit Dr. oec. Melanie Häner-Müller, Leiterin des Bereichs Sozialpolitik und Bildungsverantwortliche des Instituts für Schweizer Wirtschaftspolitik IWP an der Universität Luzern
Spätestens, wenn die Gesundheitsministerin oder der Gesundheitsminister die Krankenkassenprämien kommuniziert, entfacht sich die Debatte um die Solidarität im Gesundheitswesen neu. Doch was genau bedeutet Solidarität im Gesundheitswesen, und wie lässt sie sich messen? Darüber und über die komplexe Umverteilungssituation – sowohl auf der Finanzierungs- als auch auf der Leistungsseite – sprechen wir mit Dr. Melanie Häner-Müller. Sie ist Ökonomin, leitet den Bereich Sozialpolitik am Institut für Schweizer Wirtschaftspolitik...
2025-02-0636 min
Salud, leyes y sociedadBig Pharma's dark secrets: the Novartis scandalIt was New Year's Day 2017 in Greece, where a terrible event brought to light one of the country's biggest pharmaceutical scandals. It soon emerged that this was not a problem unique to Greece. Main sources: [1] Former Novartis execs cleared of Greek bribery charges https://www.fiercepharma.com/pharma/former-novartis-execs-cleared-greek-bribery-charges-after-years-long-investigation [2] Greece steps up Novartis corruption probe after suicide attempt https://pmlive.com/pharma_news/greece_steps_up_novartis_corruption_probe_after_suicide_attempt_1183335/ [3] Greece Files 214-Million-Euro Lawsuit Against Novartis over Bribery https://www.occrp.org/en/news/greece-files-214-million-euro-lawsuit-against-novartis-over-bribery [4] Greece investigates Novartis for alleged bribery...
2025-01-0808 minSalud, leyes y sociedadLos oscuros secretos de Big Pharma: El escándalo de NovartisEra el día de Año Nuevo de 2017 en Grecia, donde un terrible suceso sacó a la luz uno de los mayores escándalos farmacéuticos del país. Pronto se descubrió que no era un problema exclusivo de Grecia. Fuentes principales: [1] Former Novartis execs cleared of Greek bribery charges https://www.fiercepharma.com/pharma/former-novartis-execs-cleared-greek-bribery-charges-after-years-long-investigation[2] Greece steps up Novartis corruption probe after suicide attempt https://pmlive.com/pharma_news/greece_steps_up_novartis_corruption_probe_after_suicide_attempt_1183335/[3] Greece Files 214-Million-Euro Lawsuit Against Novartis over Bribery https://www.occrp.org/en/news/greece-files-214-million-euro-lawsuit-against-novartis-over-bribery[4...
2025-01-0510 min
Quarterly BriefingS01-Pharm-E07: Novartis 3Q 2024In this episode of 'The Quarterly Briefing', dive deep into Novartis' Q3 2024 earnings report powered by AI. The briefing covers impressive financial highlights, including a 10% growth in sales and 20% in core operating income. Experts discuss the factors behind Novartis' robust performance, examining key drugs like Entresto, Cosentyx, Kesimpta, and Kisqali, as well as upcoming launches like Pluvicto. The discussion also touches on the challenges posed by patent expirations and their proactive strategies in gene therapy, cell therapy, and other innovative fields. Emphasizing their commitment to ethical business practices and patient access, this episode portrays Novartis as a dynamic pharmaceutical...
2024-12-3024 min
The Influencers: Digital TransformationEthical AI in Pharma: How Novartis Leads in Data Privacy I Franziska Janorschke, Head of Data Privacy at NovartisA must-listen for anyone interested in the intersection of technology, healthcare, and ethics, this episode of The Influencers features Franziska Janorschke, Head of Data Privacy at Novartis, discussing the pharmaceutical giant's approach to digital transformation, AI, and data governance with Hogan Lovells host Leo von Gerlach. They explore Novartis' proactive stance on AI compliance, the challenges of AI implementation in complex fields like clinical trials, and how privacy and governance frameworks provide a foundation for responsible innovation.
About Novartis: Novartis is an innovative medicines company whose medicines reach more than 250 million people worldwide and that wo...
2024-12-0423 min
Gesundheitspolitik im FokusTrailer «Gesundheitspolitik im Fokus»Der Gesundheitspodcast von Bristol Myers Squibb, Biogen Switzerland AG, MSD Switzerland und Novartis Pharma Schweiz | Moderation: Heike Scholten
Das Schweizer Gesundheitswesen zählt weltweit zu den besten, doch es steht auch vor grossen Herausforderungen. Gesellschaftliche, technologische und wirtschaftliche Veränderungen erfordern Anpassungen. Was darf Gesundheit kosten? Wie bleibt das Gesundheitswesen fit? Was ist uns die Gesundheit wert? Wir sprechen mit Expertinnen und Experten aus dem Gesundheitswesen, der Politik und aus der Wissenschaft über relevante gesundheitspolitische Themen, medizinische Fortschritte und darüber, wie wir die Balance zwischen hochstehender Versorgung und nachhaltiger Finanzierbarkeit schaffen. Gesundheitspolitik im Fokus – der Podcast für alle, denen e...
2024-05-1301 min
The Life Science RundownLeading Through Transition: Strategic Insights from Novartis's Front LinesThe FDA Group's Nick Capman sits down with Stephen Poor, a physician-scientist with over 20 years of experience in the industry, mainly with Novartis — currently serving as Novartis's Global Program Clinical Head (Executive Director).
They delve into the psychological and professional impacts of organizational changes, particularly focusing on identity and adaptation during times of transition, such as layoffs or department closures.
Discussion points include:
» Stephen's transition due to organizational shutdown and his journey through change.
» Stephen's experiences and thought processes from realizing Novartis's exit from ophthalmology to starting a new job, focusing on id...
2024-04-0147 min
The Scrubbed In Show by Peerr155: Navigating the Pharma Landscape of Leadership, Trust and Collaboration - Samuel Hollis (Novartis UK - Business Unit Head)In this week's episode, Samuel shares his journey in the pharmaceutical industry, a career spanning close to 2 decades working in the UK, Switzerland and US covering roles from sales rep, medical affairs to global marketing and business unit head to now gearing up to start as a country president in Central Europe, not to mention his 🦞 theory!
We discussed:
🏥 The role of medical affairs and why people should join the industry
🌟 Why 21st century leadership is about authenticity, vulnerability and entrepreneurship
💊 The process of a medicine coming to market
🇬🇧🇺🇸 Learnings from working in the UK vs US
🔬 Th...
2024-03-2049 min
The Data Malarkey PodcastHow can a beginner's mind and a collaborative approach make you win at the team sport of "insight"? With Mark Montgomery, Novartis' Head of Integrated InsightsIn this episode of the Data Malarkey podcast, data storyteller Sam Knowles is joined by Mark Montgomery, Vice President and International Head of Integrated Insights at Novartis, a role he's held for the past three years. Mark has a rich and varied career in pharma, having served as the Global Head of Commercial Analytics and Insights at GSK before joining Novartis, following a seven-year spell at AstraZeneca in digital, data, and strategic planning. Before working in pharma, Mark spent a decade in creative, content strategy, and brand management in three different agencies. Mark holds both...
2024-01-3135 min
BaZ direktNovartis-Knall bei Rotblau: «Der FCB ist ein normaler 08/15-Club geworden»Schon im Frühsommer informierte Novartis die FCB-Verantwortlichen, dass man den Vertrag als Hauptsponsor per Ende Juni 2025 auslaufen lassen werde, um sich künftig nur noch in viel kleinerem Rahmen beim rotblauen Nachwuchs und in der Frauenfussball-Abteilung zu engagieren. Die Redimensionierung dieses Engagements als branchenüblichen Vorgang zu deuten, sei völlig falsch, findet BaZ-Chefredaktor Marcel Rohr.«Auch Novartis kämpft mit Imageproblemen. Aber klar: Der FCB hat in den letzten Jahren massiv an Attraktivität verloren, ist zu einem normalen 08/15-Club geworden», betont er im Gespräch mit «BaZ direkt»-Host Benjamin Wirth. Für den Verein werde...
2023-12-0114 min
PharmaSource PodcastNovartis Global Biotech Cooperations: a Worldwide CDMO Partner, interview with Rathish RavindrakumarNovartis has been active in the contract manufacturing space for twenty years, now under the brand name Global Biotech Cooperations.
Novartis Global Biotech Cooperations provides contract manufacturing services across various domains, including Cell & Gene Therapy, Plasmid DNA, RNA, mRNA, SiRNA, Microbial manufacturing, Mammalian cell cultures, Viral vector, and Fill & Finish.
In this episode Rathish Ravindrakumar, Business Development Director, Novartis Global Biotech Cooperations, explains how in the last 2-3 years they have been receiving more requests for newer technologies like Cell and Gene Therapy.
“These technologies represent both an opportunity and a ch...
2023-10-1806 min
Digital HR Leaders with David GreenHow Novartis Use People Data to Navigate Business Transformation (an Interview with Ashish Pant)In this episode of the Digital HR Leaders Podcast, your host David Green explores the transformative power of data-driven HR decision-making in one of the world's leading pharmaceutical companies, Novartis. Joined by Ashish Pant, Global Head of People Analytics and Data at Novartis, David and Ashish unravel how Novartis has harnessed the full potential of data to revolutionize its approach to HR. Throughout this episode, you can expect to learn more about: How Novartis strategically laid the groundwork for harnessing the full potential of HR data and analytics Invaluable...
2023-09-2654 min
South Asian TrailblazersLIVE: Vas Narasimhan (CEO of Novartis) & Dr. Srishti Gupta Narasimhan (Physician Leader in Health and Education)To kick off South Asian Trailblazers Season 7, power duo Dr. Vas Narasimhan (CEO of Novartis) and Dr. Srishti Gupta Narasimhan (Physician Leader in Health & Education) join Simi all the way from Basel, Switzerland for a LIVE recording at Novartis Headquarters in Cambridge, MA. WATCH this episode on YouTube.South Asian Trailblazers is dedicated to elevating leading South Asians. To learn about our events, subscribe to our newsletter at SouthAsianTrailblazers.com and follow us on Instagram, LinkedIn
2023-09-191h 13
Looking OutsideLooking Outside Openness: Marcel Braun, Pharmacist & Novartis Exhibition DirectorIn this episode of Looking Outside we explore living your life and career curiously through an openness to learning with trained pharmacist and director of the Novartis Pavillon exhibiting the wonders of medicine, Marcel Braun. Marcel studied pharmacy but throughout his career has remained open to entering new fields and living in new places, something he calls both accidental in drifting from one opportunity to another, and intentional as he ticked off ‘dream roles’ from his bucket list. From roles in forensic accounting, corporate philanthropy, even national pharmacist for Vanuatu, and across disciplines ranging business administration, biology and c...
2023-08-0843 min
Good News To Go: Health & WellnessAnthony (Tony) Yadao, VP of Medical Affairs for Immunology NovartisGood News was invited to the Tribeca premiere of The Beacons: Illuminating HS Stories. We now have the opportunity to speak to Anthony (Tony) Yadao, VP of Medical Affairs for Immunology Novartis.Anthony Yadao, MD is the US Medical Affairs Head for Immunology at Novartis. During his 16 years at Novartis, he has led multiple product launches ranging from small molecules to biologics, from primary care to specialist indications. Over the last 6 years, Tony has moved into therapeutic area leadership, with purview over the...for video and more info, go to http://pausetheworldforpeace.org/2023/06/26/anthony-tony-yadao-vp-of-medical-affairs-for-immunology-novartis/...
2023-06-2616 minGood News To Go: Health & WellnessAnthony (Tony) Yadao, our VP of Medical Affairs for Immunology NovartisGood News was invited to the Tribeca premiere of The Beacons: Illuminating HS Stories. We now have the opportunity to speak to Anthony (Tony) Yadao, our VP of Medical Affairs for Immunology Novartis.Anthony Yadao, MD is the US Medical Affairs Head for Immunology at Novartis. During his 16 years at Novartis, he has...for video and more info, go to #tonyyadao #anthonyyadao #medicalaffairs #immunologynovartis #beacons #immunology #novartis #hs #hidradenitissuppurativa #painfullumps #skin #research
2023-06-2616 min
Global ValueNovartis AG Stock Analysis | NVS Stock | $NVS Stock Analysis | Best Dividend Stock to Buy Now?In this video, we'll perform a NVS stock analysis and figure out what the company looks like based on the numbers. We'll also try to figure out what a reasonable fair value is for NVS. And answer is Novartis AG one of the best dividend stocks to buy at the current price? Find out in the video above! Global Value's Novartis AG stock analysis.
Check out Seeking Alpha Premium and score an annual plan for just $119 - that's 50% off! Plus all funds from affiliate referrals go directly towards supporting the channel!
Affiliate...
2023-03-2114 min
Think Tech#050 A tecnologia como aliada no tratamento de doenças raras | Marcio Ramos (Novartis)Quando aplicada à indústria farmacêutica, a tecnologia permite que tratamentos cheguem com maior eficiência na última ponta, que é o paciente. Para isso, a Novartis se estrutura com três times: dados, omnichannel e inovação. Dados do mercado da indústria farmacêutica brasileira: https://www.inovafarma.com.br/blog/mercado-farmaceutico-no-brasil/. Com: Marcio Ramos, diretor de Dados, Digital e Inovação da Novartis. Perfil no Linkedin: https://www.linkedin.com/in/ramosmarcio. Site da Novartis: https://www.novartis.com.br/Apresentação: Cassio Politi. Perfil no LinkedIn: https://www.linkedin.com/in/cassiopoliti/.
2022-10-2739 min
Event Design Collective PODcastsNelly Riggenbach - Novartis - #DESIGNtoCHANGE PODcast BACKstage - Designer Series - Ruud JanssenIn this special episode recorded onsite at the Novartis Campus in Basel, Switzerland, Nelly Riggenbach, responsible for the Novartis Experience speaks with Ruud Janssen of the Event Design Collective.
Nelly is a notoriously curious audience ambassador and storyteller. She has an entrepreneurial spirit, strong people skills and an appetite for change.
Nelly explains how the Novartis Campus (30 football fields in size) in Basel, Switzerland is now opening up to the general public.
See the link to the Novartis Pavillon which is the newest addition to the Novartis Campus here: https://www.campus.novartis.com/en/novartis-pavillon
For more details on...
2022-10-2008 min
Event Design Collective PODcastsNelly Riggenbach - Novartis - #DESIGNtoCHANGE PODcast ONstage - Designer Series - Ruud JanssenIn this special episode recorded onsite at the Novartis Campus in Basel, Switzerland, Nelly Riggenbach, responsible for the Novartis Experience speaks with Ruud Janssen of the Event Design Collective.
Nelly is a notoriously curious audience ambassador and storyteller. She has an entrepreneurial spirit, strong people skills and an appetite for change.
Nelly explains how the Novartis Campus (30 football fields in size) in Basel, Switzerland is now opening up to the general public.
See the link to the Novartis Pavillon which is the newest addition to the Novartis Campus here: https://www.campus.novartis.com/en/novartis-pavillon
For more details on...
2022-10-2058 min
Knowledge Cast by Enterprise KnowledgeBarry Byrne - Global Head of Knowledge Management Strategy at NovartisEnterprise Knowledge CEO Zach Wahl speaks with Barry Byrne, Global Head of Knowledge Management Strategy at Novartis, one of the world’s largest pharmaceutical companies. He joined Novartis from the Irish Defence Forces, where he led a multi-award winning Knowledge Management program as the Chief Information and Knowledge Management Officer.
In conversation with Zach, Barry discusses the importance of leadership in KM programs, he also speaks about Novartis' focus on connecting the dots across different KM efforts in Novartis globally and how powerful communities have been in this journey. Technology is also a big focus for Barry's te...
2022-08-1644 min
MedForumMEDUCATION MX | Hipertensión ArterialUno de los asesinos silenciosos, la hipertensión arterial pasa desapercibida durante años hasta que aparecen desenlaces secundarios derivados del descontrol de la misma. El doctor Hugo Radillo esquematiza, descompone y explica de forma muy práctica las complejidades de esta patología, de alta prevalencia en México y Latinoamérica, para preparar el Examen Nacional de Aspirantes a Residencias Médicas.
Recuerda que puedes escuchar las ponencias completas del 2021 en https://cursos.medforum.com.mx/ y ahí mismo puedes inscribirte en la edición 2022 del curso Meducation MX que inició el 28 de marzo del 2022
P3: M...
2022-08-0333 min
MedForumMEDUCATION MX | MeningitisAl tratarse de una infección que condiciona la vida del paciente como complicación mortal en el Sistema Nervioso Central, el médico de primer contacto necesita identificar los datos clínicos clave para realizar una referencia oportuna de pacientes con esta patología. El doctor Mauricio Ambriz explica los puntos clave a tomar en cuenta para preparar el Examen Nacional de Aspirantes a Residencias Médicas.
Recuerda que puedes escuchar las ponencias completas del 2021 en https://cursos.medforum.com.mx/ y ahí mismo puedes inscribirte en la edición 2022 del curso Meducation MX que inició el 28 de m...
2022-07-2717 min
MedForumMEDUCATION MX | Criterios y clasificación de LupusDentro de los diagnósticos diferenciales de patologías del tejido conectivo, el Lupus suele ser confundido en el abordaje para médicos de primer contacto. La doctora Ivette Calderón explica de manera muy práctica y concisa los puntos clave sobre Lupus en preparación para el Examen Nacional de Aspirantes a Residencias Médicas.
Recuerda que puedes escuchar las ponencias completas del 2021 en https://cursos.medforum.com.mx/ y ahí mismo puedes inscribirte en la edición 2022 del curso Meducation MX que inició el 28 de marzo del 2022
P3: MX2206096244
Fecha de vigencia...
2022-07-2026 minProgress, Potential, and Possibilities Podcast / ShowDr. Stephen Moran, PhD - Reimagining Nuclear Medicine - Advanced Accelerator Applications, NovartisSend us Fan MailDr. Stephen Moran, Ph.D., is Global Program Head, Neuroendocrine Tumors & Other Radiosensitive Cancers, for Advanced Accelerator Applications (AAA - https://www.adacap.com/), a Novartis company and also a member of the Oncology Development Unit Leadership Team at Novartis. Prior to joining AAA, Dr. Moran was Global Head of Novartis Strategy, where he played a key role in defining the company’s strategy, prioritizing critical actions needed to deliver on the mission to discover new ways to extend and improve peoples’ lives. He also led numerous strategic initiatives, including gene therapy (AveXis, now...
2022-07-1839 min
MedForumMEDUCATION MX | Ulcera pépticaEl vertiginoso ritmo de vida actual, sumado a hábitos alimentarios poco favorables han aumentado la incidencia de úlcera péptica, el doctor Jorge Lira aborda desde el punto de vista clínico, práctico y conciso esta patología tomando en cuenta los puntos clave en la preparación del Examen Nacional de Residencias Médicas.
Recuerda que puedes escuchar las ponencias completas del 2021 en https://cursos.medforum.com.mx/ y ahí mismo puedes inscribirte en la edición 2022 del curso Meducation MX que inició el 28 de marzo del 2022
P3: MX2206096244
Fecha de vigencia...
2022-07-1321 min
MedForumMEDUCATION MX | Enfermedades exantemáticas parte 2El desarrollo de enfermedades exantemáticas es un evento esperado en la vida del paciente pediátrico, desde el punto de vista de semiología hasta el abordaje diagnóstico e identificación correcta de las manifestaciones clínicas de las que se presentan con mayor frecuencia en la consulta de primer contacto, en esta segunda parte el doctor Ivan Castillo continúa con la revisión breve pero muy completa del tema.
Recuerda que puedes escuchar las ponencias completas del 2021 en https://cursos.medforum.com.mx/ y ahí mismo puedes inscribirte en la edición 2022 del curso Meduc...
2022-07-0632 min
MedForumMEDUCATION MX | Enfermedades Exantemáticas parte 1El desarrollo de enfermedades exantemáticas es un evento esperado en la vida del paciente pediátrico, desde el punto de vista de semiología hasta el abordaje diagnóstico e identificación correcta de las manifestaciones clínicas de las que se presentan con mayor frecuencia en la consulta de primer contacto, el doctor Ivan Castillo hace una revisión breve pero muy completa.
Recuerda que puedes escuchar las ponencias completas del 2021 en https://cursos.medforum.com.mx/ y ahí mismo puedes inscribirte en la edición 2022 del curso Meducation MX que inició el 28 de marzo del 2022
2022-06-3024 min
MedForumMEDUCATION MX | DIARREA AGUDALa diarrea aguda se caracteriza por incremento en el número de deposiciones (más de 2 a 3 en el día), con alteración en la consistencia, típicamente líquidas, que pueden o no presentar algún grado de deshidratación y que de acuerdo al agente causal pueden estar acompañadas de moco y sangre y estar asociadas o no con síntomas generales como fiebre, escalofrío, náuseas o cólicos abdominales, y con una duración no mayor a 14 días.
El doctor Braulio Guillén, pediatra general, aborda de manera práctica y concisa l...
2022-06-0823 min
MedForumMEDUCATION MX | Diabetes Mellitus tipo 1 y 2La diabetes mellitus es un grupo de enfermedades caracterizadas por hiperglucemia como consecuencia de defectos en la secreción y/o acción de la insulina. La hiperglucemia crónica se asocia con lesiones a largo plazo en diversos órganos, particularmente ojos, riñón, nervios, vasos sanguíneos y corazón.
Diversos procesos patológicos están involucrados en el desarrollo de diabetes mellitus, aunque la gran mayoría de los casos pueden incluirse en dos categorías. En la primera de ellas, diabetes mellitus tipo 1, la causa es una deficiencia absoluta en la secreción de insulina, a m...
2022-06-0116 min
MedForumMEDUCATION MX | AbortoDel 15 al 20% de los embarazos que se diagnostican clínicamente se pierden en el primer trimestre o al inicio del segundo, sin ninguna repercusión materna. Existen múltiples factores y causas tanto de origen fetal como materno o paterno que producen alteraciones y llevan a pérdida del producto de la gestación
El aborto no solo condiciona la vida del feto en gestación, también pone en riesgo la integridad de la madre.
En este nuevo episodio de la serie Meducation, el doctor Iván González realiza una revisión de puntos clav...
2022-05-2522 min
MedForumMEDUCATION MX | Alergia a la proteína de la leche de vacaLa alergia a la proteína de la leche de vaca (APLV) conduce a una gran variedad de manifestaciones clínicas, entre las que predomina el compromiso digestivo. La alergia alimentaria puede ser mediada por anticuerpos de tipo inmunoglobulina E (IgE), no mediada por la IgE o mediada por mecanismos mixtos.
Durante el primer año de vida, la APLV es la forma más frecuente de presentación de la alergia alimentaria y sus síntomas pueden ser inespecíficos: reflujo gastroesofágico (RGE) patológico, sangre en las deposiciones, inapetencia, dolor abdominal tipo cólico, diarrea, es...
2022-05-1840 min
MedForumMEDUCATION MX | Cáncer de mamaEl cáncer de mama continúa siendo la principal causa de muerte en mujeres mexicanas.
En este nuevo episodio de la serie Meducation MX, el doctor Fermin Barba revisa los puntos más importantes a considerar para una identificación y abordajes oportunos para el médico de primer contacto.
Recuerda que puedes escuchar las ponencias completas del 2021 en https://cursos.medforum.com.mx/ y ahí mismo puedes inscribirte en la edición 2022 del curso Meducation MX que inició el 28 de marzo del 2022
P3: MX2204278962
Fecha de vigencia: 31/12/2022
Material...
2022-05-1117 min
MedForumMEDUCATION MX | Hemorragia de la segunda mitad del embarazoSe define como hemorragia de la segunda mitad del embarazo al sangrado que tiene lugar después de las 22 semanas de gestación. Las causas más frecuentes son placenta previa (PP) y desprendimiento prematuro de placenta (DPP), menos frecuentes son rotura uterina (RU), rotura del seno marginal y vasa previa
En este nuevo episodio de la serie Meducation MX, el doctor Ivan González realiza una revisión de lo más relevante a considerar en el abordaje de esta complicación del embarazo.
Recuerda que puedes escuchar las ponencias completas del 2021 en https://cursos.m...
2022-05-0426 min
MedForumMEDUCATION MX | Enfermedad Renal CrónicaLa enfermedad renal crónica constituye actualmente un problema de salud pública en nuestro país, debido a su alta prevalencia y altos costos que de ella derivan. El conocimiento de la definición y clasificación de la enfermedad constituye un punto importante en el diagnóstico temprano y tratamiento oportuno de la enfermedad.
En este nuevo episodio de la serie Meducation MX, el doctor Antonio Mariano, nos comparte de manera breve pero detallada los puntos clave a considerar en pacientes con esta enfermedad crónica.
Recuerda que puedes escuchar las ponencias completas del 2021...
2022-04-2930 min
MedForumMEDUCATION MX | Hepatitis viral parte 2La hepatitis viral aguda es una inflamación generalizada del hígado causada por virus hepatotrópicos específicos que se caracterizan por diversos modos de transmisión y diferentes epidemiologías. Existen al menos seis tipos diferentes de hepatitis pero las tres más comunes son hepatitis A , hepatitis B y hepatitis C.
El doctor Jorge Emilio Lira, hepatólogo y experto en el tema, realiza una revisión completa de hepatitis virales y comparte con nosotros los puntos clínicos clave a tomar en cuenta para el Examen Nacional de Residencias Médicas.
Recuerda qu...
2022-04-0618 min
MedForumMEDUCATION MX | Hepatitis viral Parte 1La hepatitis viral aguda es una inflamación generalizada del hígado causada por virus hepatotrópicos específicos que se caracterizan por diversos modos de transmisión y diferentes epidemiologías. Existen al menos seis tipos diferentes de hepatitis pero las tres más comunes son hepatitis A , hepatitis B y hepatitis C.
El doctor Jorge Emilio Lira, hepatólogo y experto en el tema, realiza una revisión completa de hepatitis virales y comparte con nosotros los puntos clínicos clave a tomar en cuenta para el Examen Nacional de Residencias Médicas.
Recuerda que...
2022-04-0120 min
MedForumMEDUCATION MX | Faringitis, Otitis Media Aguda, Sinusitis, NeumoníaEn este quinto podcast de la serie Meducation MX el doctor Ivan Castillo realiza una revisión breve, pero muy completa de temas relevantes en infectología pediátrica, con los puntos clave que se deben tomar en cuenta en la identificación clínica de las infecciones de vías respiratorias en pediatría y con tips para los aspirantes al Examen Nacional de Residencias Médicas.
Lo invitamos a registrarse en https://cursos.medforum.com.mx/ para ser parte de la próxima edición del curso Meducation MX
P3: MX2203228818
Fecha de v...
2022-03-2929 min
MedForumMEDUCATION MX | Ictericia NeonatalAproximadamente el 50-60% de neonatos presentan hiperbilirrubinemia y la mayoría de los recién nacidos desarrollan ictericia clínica luego del segundo día de vida como expresión de una condición fisiológica. La ictericia en la mayoría de los casos es benigna, pero por su potencial neurotoxicidad, debe ser monitorizada muy de cerca para identificar neonatos que pueden desarrollar hiperbilirrubinemia severa y alteraciones neurológicas inducidas por la bilirrubina.
En esta cuarta entrega de la serie Meducation MX, el doctor Israel Zamora comparte con nosotros los puntos clave a tener en cuenta en el dia...
2022-03-2624 min
MedForumMEDUCATION MX | Trastornos hipertensivos del embarazoLos trastornos hipertensivos del embarazo hacen referencia a las alteraciones fisiopatológicas, las cuales generan un aumento de la presión arterial, que conllevan diversas complicaciones maternas y fetales. En la actualidad los trastornos hipertensivos en el embarazo, como la hipertensión gestacional, preeclampsia y eclampsia, son primordiales, debido al riesgo elevado de morbimortalidad materna y fetal, por lo que es elemental el diagnóstico precoz, así como su manejo para obtener la mejor eficacia en el control, disminución de las complicaciones y de su morbimortalidad.
En este tercer podcast de la serie Meducation MX, el doctor...
2022-03-2427 min
MedForumMEDUCATION MX | Diabetes GestacionalLa diabetes gestacional es un padecimiento de la mujer caracterizado por intolerancia a los carbohidratos, que resulta en hiperglucemia de severidad variable, que se inicia y reconoce durante el embarazo. La diabetes gestacional se asocia con incremento del riesgo de padecer trastornos hipertensivos del embarazo, nacimientos por vía cesárea y morbilidades asociadas con la diabetes.
Esta enfermedad no solo causa complicaciones en la mujer sino también en el producto, algunas de las más comunes son macrosomía fetal, hipoglucemia neonatal, hiperbilirubinemia, distocia de hombro, trauma fetal durante el nacimiento y muerte fetal-neonatal.
En...
2022-03-1822 min
MedForumMEDUCATION MX | Infecciones Vaginales, EPI y Sx de Ovario PoliquísticoLas infecciones vaginales, la enfermedad pelvica inflamatoria y el síndrome de ovario poliquístico son algunos de los motivos de consulta más comunes en la práctica médica diaria no solo del ginecólogo sino también del médico de primer contacto.
El Dr Fermín Barba, especialista en ginecología y obstetricia y actual profesor del curso MeducationMx, comparte con nosotros en este primer podcast los puntos más relevantes a tomar en cuenta para la prevención, diagnóstico y manejo oportunos de estas patologías basado en las Guías de Práctica Clíni...
2022-03-1623 min
SoonishHow Novartis Built a Hit Factory for New DrugsWhen you hear people use the phrase "It's a hits-driven business," they're usually talking about venture capital, TV production, videogames, or pop music—all industries where you don't make much money unless you come up with at least one (and preferably a string of) massively popular products. But you know what's another hits-driven business? Drug development. This week, we present the fourth and final episode in the Persistent Innovators miniseries, originally produced for InnoLead's Innovation Answered podcast and republished here for Soonish listeners. It's all about the giant Swiss pharmaceutical company Novartis, maker of more than a dozen blockbuster dru...
2022-03-121h 00
Innovation AnsweredWhat Makes Novartis a Persistent Innovator?How do big companies stay innovative across many decades, and in different industries? That’s been the driving question of our Persistent Innovators miniseries. In the fourth and final episode we turn to company in a very different kind of business: discovering and developing new drugs. And we focus on the global pharmaceutical giant Novartis, formed in 1996 from the merger of the venerable Swiss companies Sandoz and CIBA-Geigy. At its Novartis Institutes for BioMedical Research, opened in 2002, Novartis invented a new style of biology-centric drug discovery that has changed practices across the industry—and sparked a local biopharma boom that...
2022-02-2856 min
Digital HR Leaders with David GreenHow Novartis is Building a Skills Operating System for Workforce Planning (René Gessenich, Novartis)This week’s podcast guest is René Gessenich, Head of Strategic Workforce Planning at Novartis, who shares the work that he’s been doing to build a skills operating system for workforce planning at Novartis.In this episode, René and I discuss: Why having a robust skills ontology is so importantHow to incorporate internal and external skills data, in a single skills ontologyNovartis's approach to skills-based workforce planning with some examples of their targeted approachSpecific advice for organisations looking to adopt a skills-based approach to workforce planningSupport for this podcast comes...
2022-02-0842 min
MedForum3. Manejo de la dislipidemia en pacientes con insuficiencia renalLa enfermedad cardiovascular (ECV) es la principal causa de morbilidad y mortalidad en los pacientes con insuficiencia renal crónica (IRC). Este riesgo cardiovascular elevado comienza en etapas iniciales de IRC, antes de que se desarrolle la insuficiencia renal avanzada.
Acompañe a la Dra Verónica Guzmán MSL de Novartis y al Dr. Rafael Valdez jefe del servicio de Nefrología del Hospital General de México en este nuevo episodio donde comparten con nosotros información relevante sobre el manejo de la dislipidemia en pacientes con insuficiencia renal, ¿qué debemos considerar?, ¿requieren ajuste de dosis en s...
2022-02-0117 min
MedForum2. Abordaje de la dislipidemia en pacientes con ObesidadLa obesidad es un problema grave de salud pública, con una elevada prevalencia y que se relaciona de forma estrecha con la elevación del riesgo de desarrollar una enfermedad cardiovascular aterogénica. En este episodio la Dra. Verónica Guzman; MSL de Novartis, de la mano del Dr. Pedro Mendoza; especialista en Diabetes y metabolismo, nos compartirán información relevante sobre los principales factores bio-psicosociales que contribuyen al desarrollo de la obesidad y cómo podemos mejorar nuestro acercamiento con los pacientes que padecen esta patología.
Ingrese a www.medforum.com.mx si quiere co...
2022-01-1131 min
The Leader Unmasked Podcast#79 - Eleanor Foley - Solution Delivery Manger, NovartisA Human Connection: Beating the Odds through Kindness
As women, we tend to underestimate our capabilities when pursuing a professional career. Our self-esteem further diminishes when people belittle our accomplishments because of our gender. However, the key to success doesn't lie in your origin or gender but your strengths. Everyone can reach the same heights and create the human connections necessary to get to the top. Eleanor Foley is an inspirational figure who proves that success is always within reach, no matter the odds.
In this episode, Eleanor Foley describes her challenging journey as a s...
2021-12-1346 min
MedForum1. Manejo de la dislipidemia en pacientes con síndrome metabólicoEn este primer podcast la doctora Verónica Guzmán MSL de Novartis y el Dr. Gustavo Solache Ortíz, médico especialista en cardiología, nos comparten información muy interesante sobre el manejo de la dislipidemia en pacientes con síndrome metabólico. Acompáñenos en esta charla donde se abordarán temas como la epidemiología del síndrome metabólico y la dislipidemia en México, los factores de riesgo más importantes para estas patologías, la importancia de su diagnóstico y su impacto en la enfermedad cardiovascular.
Ingrese a www.medforum.com.mx si...
2021-12-1019 min
Die BörsenminuteNovartis verkauft Roche: Zwei sind doch besser wie einsDer Traum oder Alptraum eines Schweizer Mega-Pharmakonzerns, der den Onkologiemarkt beherrscht ist endgültig geplatzt. Anfang November nutzte Novartis die Gunst der Stunde, um bei den hohen Börsenkursen sein Aktien-Drittel an Roche nach 20 Jahren an die Roche-Erben zu verkaufen. Der Familien-Clan besitzt nun 67,5 Prozent der Stimmrechte an dem Schweizer Börsenschwergewicht. Familie Roche, die 19 Milliarden für den Rückkauf eigener Aktien zahlte, vernichtete sie kurzerhand, um ihren Einfluss im eigenen Unternehmen zu erhöhen. Und was bedeuten die getrennten Wege für den jeweiligen Aktienkurs? Der Konsensus der Analysten sieht die Entflechtung der Pharmariesen positiv. Novartis will mit dem...
2021-11-1702 min
Hot Bets - der Podcast über heiße AktienTrade der Woche – Long auf Novartis (PZ70Q6) und BioNTechHot Bets Episode 182 der Podcast über heiße Aktien von finanzen.net
Bei dem Podcast von finanzen.net, Hot Bets - heiße Wetten, geht es um den Trade der Woche – LONG auf Novartis (PZ70Q6) und ein Update bei BioNTech. Hört doch mal rein!
Novartis, CH0012005267
NOVARTIS Mini Long, PZ70Q6, DE000PZ70Q66
BioNTech, US09075V1026
WICHTIG: Es handelt sich bei den besprochenen Werten nicht um Anlageempfehlungen. Die hier besprochenen Aktien und Hebelprodukte bergen aufgrund hoher Volatilität ein hohes Risiko!
Werbung:
Die heutige Sendung wird unterstützt von BNP...
2021-11-1508 min
BTD: Making Sense of M&A, Alliances and DivestmentsTargeting Those Most in Need: Access-Focused Product Partnerships at NovartisAll pharmaceutical companies look to leverage their capabilities to benefit those in the World’s poorest countries. Novartis aims to go beyond corporate philanthropy to create a more sustainable therapy-development model. By marshalling partnerships and its own people, Charlie Bailey leads Novartis teams pursuing development initiatives addressing better-known conditions like malaria, as well as more obscure ones like leishmaniasis. These initiatives can span a decade or more taking therapies through Phase I, II and III clinical trials, then ensuring the infrastructure and skills to offer them in the world’s most remote locations.In this fascinating podcast, Char...
2021-09-1653 min
Expedition ArbeitExpedition Arbeit #59 - Matthias Meifert von hr pepper im Interview // Unboss your company: Seriously, Novartis?Die Sendung 59 im Überblick 00:00 SHOW INTRO Florian Städtler 04:55 MITGLIEDER-STECKBRIEF DER WOCHE: Arne Schröder aus Bremen 10:20 NACHGEHAKT: Interview mit Matthias Meifert von hr pepper zur Debatte mit Stefan Kühl 22:59 LIVE DABEI (1): Unbossed - ein Employer Branding-Promo-Event des Pharmariesen Novartis 26:17 THESE DER WOCHE: Unboss your company. Seriously, Novartis? 28:27 LIVE DABEI (2): DATEV lernt - vier neue Barcamp-Termine für 2022 online 30:00 SHOW INTRO Florian Städtler Das Community Radio für Neue Arbeit und Wirtschaft Expedition Arbeit präsentiert sein Community Radio für Neue Arbeit, moderiert von Florian Städtler. Jeden Montag erscheint dieser Podcast und präsentiert Nachrichten und Meinungen r...
2021-08-2931 min
The EY PodcastCEO Outlook: The future of pharma with Audrey Derveloy, Novartis IrelandAs a young science graduate, Audrey Derveloy’s goal was to have a positive impact on society. Now, as a leader of a global medicines company during a world-wide pandemic, that dream is being realised. Novartis employs 1,400 people in Ireland, and the company uses innovative science and digital technologies to create transformative treatments in areas of great medical need such as Cardiology, Oncology and Immunology. Having spent several years in leadership roles at Novartis in France, Audrey was offered the role of General Manager and Country President of Novartis Ireland in early 2020, just before the COVID-19 pandemic beg...
2021-07-2234 min
Digital HR Leaders with David GreenHow is Novartis Reinventing Performance Management? (Interview with Steven Baert)The transformation that Steven Baert is leading as Chief People and Organisation Officer at Novartis, in shaping culture and leadership to a re-imagined medicine is hugely impressive. As Steven explains in this week's episode of the podcast, Novartis is successfully fuelling a scientific and entrepreneurial spirit of the company through its inspired, curious and un-bossed culture. This equips the people closest to the customer or product with the freedom to own the important decisions about their work for themselves. Novartis is also empowering their people by re-imagining its approach to performance management. As one of the worlds foremost science...
2021-06-2239 min
Learning UncutCuriosity and Learning at Novartis – Simon BrownSimon Brown, the Chief Learning Officer at Novartis, discusses how Novartis is creating a culture of curiosity, with a particular focus on the work of the learning and development team. While the L&D team at Novartis is very big - 1,000 people globally serving a workforce of 110,000 - there is much that you can take away and adapt to an organisation of any size. Host: Michelle Ockers Transcript and related resources: https://learninguncut.global/podcast/77/ Podcast information and more episodes: https://learninguncut.global/podcast/ Emergent: Podcast information and more e...
2021-04-2656 min
AGORACOM Small Cap CEO InterviewsValeo Enters Commercialization and Supply Agreement With Novartis To Address the $700M/ Year Canadian Asthma Medication MarketValeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) announced today that it has entered into a Commercialization and Supply Agreement with Novartis Pharmaceuticals Canada Inc.for the Canadian commercialization by Valeo of two asthma therapies, Enerzair ® Breezhaler ® (indacaterol (as acetate), glycopyrronium (as bromide) and mometasone furoate) 3 and Atectura ® Breezhaler ® (indacaterol (as acetate) and mometasone furoate).
Under the Agreement, Valeo will be responsible for medical and commercial activities for an initial 8 year period.
How Significant Is This Market?
At present, almost 4 million Canadians are living with asthma a serious health issue affecting all age gr...
2021-03-2922 min
Amplifying Scientific Innovation® Video PodcastAmplifying Scientific Innovation with Dr. Mimi Huizinga, Head, US Medical Oncology, NovartisIn Episode 10, Season 3 of the Amplifying Scientific Innovation Video Podcast, Dr. Sophia Ononye-Onyia, Founder and CEO of The Sophia Consulting Firm, interviewed Dr. Mimi Huizinga, Head US Medical Oncology, Novartis, a leading global medicines company that is reimagining medicine to improve and extend people’s lives. Here, Dr. Huizinga shares personal anecdotes of her leadership journey, industry outlook and her focus on driving data, digital and health equity at Novartis. For full transcript, please visit: https://sophiaconsultingfirm.com/blogs-and-articles/f/amplifying-scientific-innovation-dr-mimi-huizinga-vp-novartis
2021-03-0830 min
Healthcare Goes DigitalRisk Management, Ethics, and Compliance Considerations in the New Normal with Myriam Prescott, Head of Ethics, Risks and Compliance – Oncology, Novartis CanadaMyriam Prescott, Head of Ethics, Risks and Compliance - Oncology, Novartis Canada, dissects the importance of effective patient engagement and strong compliance & monitoring programs. We also dive into the legal and ethical considerations around novel digital technologies, patient data ownership, remote trials, and much more.To find out more about Impetus: https://www.meetwithimpetus.comNatalie Yeadon LinkedIn: https://www.linkedin.com/in/natalieyeadon/Impetus Digital Website: https://www.impetusdigital.com/Impetus Digital LinkedIn: https://www.linkedin.com/company/impetus-digital/Impetus Digital Twitter: https://twitter.com/impetus_digital
2021-02-1555 minBTD: Making Sense of M&A, Alliances and DivestmentsPartner of Choice 2021: Alliance Management and M&A Combine Forces at NovartisJoin Novartis executives Christelle Sanglier-Bornstein, Global Head of Post-Merger Integration, and Knut Sturmhoefel, Global Head of Alliance Management, as they discuss establishing Novartis as a Partner of Choice (PoC) across its portfolio of businesses with BTD Partner, Nick Palmer. Download our podcast to find what Alliance Management and M&A at Novartis are learning from each other and what they propose adding as a fourth “C” to the PoC formula: Cultural Flexibility + Collaboration + Capabilities + ...CLICK HERE to follow us on LinkedInwww.btd.consulting
2021-02-0947 min
RegTechImpactKlaus Moosmayer, Ph.D., Chief Ethics, Risk & Compliance Officer of Novartis, Basel SwitzerlandEpisode 1
Klaus Moosmayer, Ph.D.
Chief Ethics, Risk & Compliance
Officer of Novartis
[linkedin]
Nationality: German
Year of Birth: 1968
Klaus Moosmayer, Ph.D., has been Chief Ethics, Risk &
Compliance Officer of Novartis since 2018. He is a member
of the Executive Committee of Novartis.
Mr. Moosmayer previously was chief compliance officer of
Siemens AG, a position he held since 2014. During his 18-
year career at Siemens, Mr. Moosmayer also served as
chief counsel compliance from 2009 to 2013, and as
compliance operating officer from 2007 to 2009.
Mr. Moosmayer received his doctor of jurisprudence from
the University of Freiburg in Germany, and passed his first
...
2020-11-0739 min
Talking HealthTech77 - When was your last health check? Novartis Wellness Day SpecialIn this episode of Talking HealthTech, we sit down with Cheryl Maley; General Manager of Oncology For Australia, New Zealand at Novartis, Krystal Barter; CEO of Humanise Health and the founder of Pink Hope, and Holly Masters; CEO of the McGrath Foundation.
With the growing number of people avoiding getting routine checkups, health screenings, and early diagnostic tests because of the pandemic, Novartis has created the Wellness Day Campaign. It aims to motivate individuals to focus on their health for a moment during these challenging times.
Novartis is a leading global medicine company focused on innovative science, digital technologies, and...
2020-11-0530 minDigital HR Leaders with David GreenHow Novartis Promotes Learning Curiosity to Drive Business Value (Interview with Simon Brown)In this episode of the podcast my guest is Simon Brown, Chief Learning Officer at Novartis, a company that is really setting the pace around the whole learning and skills agenda. Simon believes that curiosity is the greatest driver of value in the digital age and as well as being co-author of a fascinating new book, The Curious Advantage, Simon and his team have instigated curiosity month at Novartis, an integrated learning experience of 170 events throughout September featuring internal and external speakers.In our conversation, which took place just before the start of curiosity month, Simon and I discu...
2020-10-0645 min
The Alldus Podcast - AI in ActionE121 Nimit Jain, Head of Data Science ACOE at NovartisToday's guest is Nimit Jain, Head of Data Science with the Analytics Centre of Excellence at Novartis. Novartis are reimagining medicine to improve and extend people’s lives. As a leading global medicines company with products reaching nearly one billion people globally, Novartis use innovative science and digital technologies to create transformative treatments in areas of great medical need.
With years of experience in applying innovative analytics techniques in complex environments working with Big Data, Nimit is responsible to establish and grow a Data Science team to be multi-disciplinary and globally aligned with Novartis strategy. He also supp...
2020-09-0119 min
Innovation in Compliance with Tom FoxSuparna Goswami and the Compliance Evangelist Talk Novartis on HealthCare Info Security and Fraud IOI was recently interviewed by Suparna Goswami about the Novartis corruption enforcement actions, both the US domestic and the international FCPA matter. Incidents of fraud at pharmaceutical giant Novartis that resulted in over $1 billion in fines worldwide might have been avoided if the company's compliance team used data analytics to detect patterns, says Thomas Fox, a compliance evangelist and author.The Novartis case involved illegal payments and perks provided to physicians in exchange for prescribing certain drugs.Too often, corporations' compliance teams lack access to the data that's necessary to do their jobs, Fox says in...
2020-08-0415 min
Everything ComplianceEpisode 63 - the Novartis editionWelcome to the only roundtable podcast in compliance. Today, we have the full quintet of Jonathan Armstrong, Jay Rosen, Matt Kelly, Jonathan Marks and Mike Volkov sitting in to discuss various aspects of the Novartis settlements and ending with a veritable mélange of rants and shouts outs.
Jonathan Armstrong critiques the ongoing corruption in the pharma industry and implores the industry to do business differently. Instead of a shout out, he asks that we each reach out to someone who has been laid off during the Coronavirus crisis and check in with them.
Jay Rosen considers the Novar...
2020-07-161h 04
Corruption Crime & ComplianceEpisode 150 -- Novartis Settles False Claims Act and Anti-Kickback Case for $729 Million Novartis is the new poster-child of corporate misconduct. In the space of two weeks, Novartis settled domestic False Claims Act and Anti-Kickback violations for $729 million, and settled FCPA violations for foreign bribery for $337 million.
In the domestic False Claims Act and AKS cases, Novartis resolved two separate cases: one for illegal payments made to three foundations used to pay for patients' co-payments in order to increase sales; and another for illegal payments to doctors through a false speaker program which was used to shower physicians with lavish meals, events, gifts and other benefits to induce them to i...
2020-07-1220 min
Corruption, Crime & ComplianceEpisode 150 -- Novartis Settles False Claims Act and Anti-Kickback Case for $729 MillionNovartis is the new poster-child of corporate misconduct. In the space of two weeks, Novartis settled domestic False Claims Act and Anti-Kickback violations for $729 million, and settled FCPA violations for foreign bribery for $337 million.In the domestic False Claims Act and AKS cases, Novartis resolved two separate cases: one for illegal payments made to three foundations used to pay for patients' co-payments in order to increase sales; and another for illegal payments to doctors through a false speaker program which was used to shower physicians with lavish meals, events, gifts and other benefits to induce them to increase prescriptions f...
2020-07-1220 min
Learning Is The New WorkingNovartis's Simon Brown Is Fighting COVID19 While Building a Curiosity CultureHow will COVID impact Workplace Learning? One person I thought could definitely answer that in our ongoing ‘Learning Leaders’ thematic season here at Learning Is The New Working is Simon Brown, who in 2019 became the first-ever Chief Learning Officer at focused medicines leader Novartis—and who helped move 60,000 people onto remote working in just a single weekend. With a resume that stretches from co-founding one of the UK's leading eLearning companies, Brightwave, to a senior advisory role at Accenture then leading cross-organizational Learning transformation at a major British bank, Simon joined his current employer in 2013. Since he’s been on the Nova...
2020-07-0837 minCorruption Crime & ComplianceEpisode 148 -- A Review of the Novartis & Alcon FCPA Enforcement ActionEven during this difficult time of the pandemic, economic uncertainty and social unrest, the Justice Department and the SEC have concluded a major FCPA enforcement action.
Novartis and Alcon (which was a Novartis subsidiary at the time of the misconduct) agreed to pay a total of $345 million in criminal and civil penalties. Novartis spun off Alcon in 2019.
Under the DOJ settlement, Novartis and Alcon each entered into a deferred prosecution agreement; Novartis agreed to pay a fine of $225 million and Alcon agreed to pay $8.9 million in criminal penalties. Novartis also entered into a settlement with th...
2020-06-2832 minCorruption, Crime & ComplianceEpisode 148 -- A Review of the Novartis & Alcon FCPA Enforcement ActionEven during this difficult time of the pandemic, economic uncertainty and social unrest, the Justice Department and the SEC have concluded a major FCPA enforcement action. Novartis and Alcon (which was a Novartis subsidiary at the time of the misconduct) agreed to pay a total of $345 million in criminal and civil penalties. Novartis spun off Alcon in 2019.Under the DOJ settlement, Novartis and Alcon each entered into a deferred prosecution agreement; Novartis agreed to pay a fine of $225 million and Alcon agreed to pay $8.9 million in criminal penalties. Novartis also entered into a settlement with the SEC under wh...
2020-06-2832 min